Dexmedetomidine

Generic Name: Dexmedetomidine

Brand Names: Dexdor, Igalmi, Precedex, Dexmedetomidine Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₆N_₂

CAS Number: 113775-47-6

Unique Ingredient Identifier: 67VB76HONO

Background: An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine.

Indication: Administered intravenously, dexmedetomidine is indicated for the sedation of initially intubated and mechanically ventilated patients during treatment in intensive care settings, and for the sedation of non-intubated patients prior to and/or during surgery and other procedures. It is also available as a buccally- or sublingually-administered dissolvable film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder.

Associated Conditions: Agitation, Alcohol Withdrawal Syndrome

Associated Therapies: -

Clinical Trials

Effects of Dexmedetomidine on Breast Cancer Cell Function in Vitro

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: saline
Drug: Dexmedetomidine

First Posted Date: 2017-04-11

Last Posted Date: 2017-10-10

Lead Sponsor: RenJi Hospital

Target Recruit Count: 24

Registration Number: NCT03108937

Locations: 🇨🇳
Renji Hospital, Shanghai, Shanghai, China

Brain Protection Effect of Selective Head Cooling and Dexmedetomidine in Patients Undergoing Liver Transplantation

Phase 2

Conditions: Liver Transplant; Complications

Interventions: Device: Cooling Helmet
Drug: Dexmedetomidine

First Posted Date: 2017-04-05

Last Posted Date: 2019-05-29

Lead Sponsor: Huazhong University of Science and Technology

Target Recruit Count: 100

Registration Number: NCT03102359

Locations: 🇨🇳
Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology, Wuhan, Hubei, China

Effects of Dexmedetomidine on Patients With Coronary Heart Disease After Percutaneous Coronary Intervention

Early Phase 1

Conditions: Heart Injuries

Interventions: Drug: 0.9%NaCl solution
Drug: Dexmedetomidine

First Posted Date: 2017-03-29

Last Posted Date: 2017-06-09

Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Target Recruit Count: 200

Registration Number: NCT03095469

Locations: 🇨🇳
the 1st affiliated hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

Effect of Perioperative Dexmedetomidine Administration on Outcome in Cardiac Surgery Patients

Phase 4

Completed

Conditions: Patient Outcome Assessment

Interventions: Drug: Dexmedetomidine

First Posted Date: 2017-03-27

Last Posted Date: 2019-04-11

Lead Sponsor: Moscow Regional Research and Clinical Institute (MONIKI)

Target Recruit Count: 169

Registration Number: NCT03091166

Locations: 🇷🇺
Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy, Moscow, Russian Federation

Dexmedetomidine Added to Propofol for Drug Induced Sleep Endoscopy

Phase 4

Completed

Conditions: Obstructive Sleep Apnea of Adult

Interventions: Drug: Propofol
Drug: Dexmedetomidine

First Posted Date: 2017-03-27

Last Posted Date: 2018-04-13

Lead Sponsor: Essam Fathi

Target Recruit Count: 50

Registration Number: NCT03091894

Locations: 🇪🇬
Zagazig university, Zagazig, Sharkia, Egypt

A Study to Compare the Long-term Outcomes After Two Different Anaesthetics

Phase 3

Active, not recruiting

Conditions: Anesthesia
Child Development
Neurotoxicity

Interventions: Drug: Sevoflurane
Drug: Remifentanil
Drug: Dexmedetomidine

First Posted Date: 2017-03-24

Last Posted Date: 2024-07-05

Lead Sponsor: Murdoch Childrens Research Institute

Target Recruit Count: 450

Registration Number: NCT03089905

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
The University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 18 locations